Scientists to create new human monoclonal antibody targeting protein...
Researchers have discovered a unique monoclonal antibody that can effectively reach inside a cancer cell, a key goal for these important anticancer agents, since most proteins that cause cancer or are...
View ArticlePhilip and Cheryl Milstein provide $20M to support advancement of medicine at...
Continuing their family's multigenerational connection to Columbia and support of its leadership in medicine, Philip (CC '71) and Cheryl Milstein (Barnard '82) have made a $20 million commitment to...
View ArticlePARP inhibitors can be novel treatment strategy for cisplatin-resistant cancer
Poly (ADP-ribose) polymerase inhibitors may be a novel treatment strategy for patients with cancer that has become resistant to the commonly used chemotherapy drug cisplatin, according to data from a...
View ArticleDual-signaling CAR T cells show potent anti-cancer activity in animal model
The need to distinguish between normal cells and tumor cells is a feature that has been long sought for most types of cancer drugs.
View ArticlePreclinical studies show bladder cancers, mesotheliomas respond to treatment...
Scientists from academic institutions reported at the 2013 annual American Association for Cancer Research meeting, results from preclinical studies which showed that certain bladder cancers and...
View ArticleNew collaboration to expand vaccine approaches for melanoma
Aduro BioTech, Inc. announces a collaboration with Charles G. Drake, M.D., Ph.D., Associate Professor of Oncology, Immunology and Urology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center...
View ArticleResearchers develop first portable, real-time airborne asbestos detector
Asbestos was once called a miracle material because of its toughness and fire-resistant properties. It was used as insulation, incorporated into cement and even woven into firemen's protective...
View ArticleCombination of cytoreductive surgery and HIPEC may reduce mortality in...
Researchers at Roswell Park Cancer Institute (RPCI) have determined that cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CS/HIPEC), a complex procedure to treat advanced...
View ArticleVerastem's VS-6063 gets orphan drug designation from European Commission for...
Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that VS-6063 has received orphan medicinal product designation from...
View ArticleVerastem announces initiation of VS-4718 Phase 1 trial in patients with...
Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the initiation of a Phase 1 trial of VS-4718, a novel, small molecule...
View ArticleVerastem's defactinib gets FDA orphan drug designation for treatment of...
Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that lead cancer stem cell inhibitor, VS-6063 (defactinib), has...
View ArticleEPHB2 overexpressed in malignant pleural mesothelioma cell lines, find...
Malignant mesothelioma is a rare asbestos-associated malignancy with limited therapeutic options. Despite advances in the treatment, the median survival remains 12 months from the time of diagnosis....
View ArticleVirttu Biologics treats first cohort of patients in SEPREHVIR Phase I/IIa study
Virttu Biologics Limited, a UK biotechnology company with expertise in the field of oncolytic viruses, has announced that it has treated the first cohort of patients in its Phase I/IIa clinical study...
View ArticleResearchers lead two major trials to test potential treatments for...
University of Leicester researchers are leading two major trials into treatments for a type of cancer which affects those exposed to asbestos.
View ArticleImmunologic checkpoint inhibitor shows promise in malignant mesothelioma
Tremelimumab, one of a new class of immunomodulatory monoclonal antibodies, has shown encouraging clinical activity and acceptable tolerability in patients with chemotherapy-resistant malignant...
View ArticleVerastem presents positive results from VS-6063 clinical and preclinical...
Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced positive results from the Phase 1 portion of its Phase 1/1b study of...
View ArticleFDA grants orphan drug designation to Aduro's CRS-207 for treatment of...
Aduro BioTech, Inc. announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation for CRS-207, a novel immunotherapy, for the...
View ArticlePolaris Group reports positive results from ADI-PEG 20 Phase 2 trial for...
Polaris Group announced today that positive results from a randomized Phase 2 trial of ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, for the treatment of malignant pleural...
View ArticleLoyola hospital uses new 3-D vision technology for minimally invasive lung...
Loyola University Medical Center is the first Illinois hospital to use new 3-D vision technology for minimally invasive lung surgery.
View ArticlePenn Medicine researchers show predictive power of overlooked lymph nodes
For the first time, researchers from the Perelman School of Medicine at the University of Pennsylvania have shown the predictive power of a group of overlooked lymph nodes--known as the posterior...
View Article